Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 679 across all filing types
Latest filing 2024-09-19 Interim / Quarterly Rep…
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
Rapport d'activité et financier semestriel 2024 - Rapport des Commissaires aux Comptes
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive interim financial report for Genfit covering the period from January 1 to June 30, 2024. It includes the 'Rapport des commissaires aux comptes' (Audit Report on interim financial information), the consolidated statement of financial position, income statement, statement of comprehensive income, and cash flow statement, along with detailed notes. Since it contains actual financial statements for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2024
2024-09-19 French
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'PRESS RELEASE' multiple times and announces a specific corporate event: the positive opinion from the EMA's CHMP regarding Ipsen's drug Iqirvo®. This type of announcement, detailing key operational or regulatory milestones, is typically classified as an Earnings Release (ER) if it contains financial highlights, or more generally, a Regulatory Filing (RNS) if it's a broad regulatory update. Since this is a press release announcing a significant regulatory/clinical development milestone (CHMP opinion) rather than a comprehensive financial report (10-K, IR) or a management discussion (MDA), and it is not a transcript (CT) or a formal proxy document, the most appropriate classification among the provided options for a general, timely corporate announcement of this nature is often the 'Regulatory Filings' fallback (RNS), or potentially 'Earnings Release' (ER) if interpreted broadly as a major operational update. However, given the focus is purely on a regulatory opinion and not quarterly financial results, RNS is the safest general regulatory announcement category. Since the document is substantial (over 7000 characters) and contains detailed information, it is not a simple RPA. I will classify it as RNS as it is a general regulatory announcement not covered by a more specific code like DVA or LTR.
2024-07-26 English
GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive
Regulatory Filings Classification · 100% confidence The document is explicitly titled 'COMMUNIQUÉ DE PRESSE' (Press Release) multiple times. It announces a specific, time-sensitive event: the positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding Ipsen's drug Iqirvo® (elafibranor) for Primary Biliary Cholangitis (PBC). This type of announcement, detailing a regulatory milestone or key development, is typically classified as an Earnings Release (ER) if it were financial results, or more generally, a Regulatory Filing (RNS) or a specific announcement type. Since it is a press release announcing a major regulatory step (CHMP opinion leading to potential EU marketing authorization), and it is not a full financial report (10-K, IR), a transcript (CT), or a management discussion (MDA), it fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-financial regulatory update, or potentially an Earnings Release (ER) if the database treats major regulatory news as such. Given the focus is purely on a regulatory opinion and next steps, RNS is the most appropriate general regulatory fallback. However, in many financial databases, press releases announcing key clinical/regulatory milestones are often grouped with Earnings Releases (ER) as they are primary investor communications about performance drivers. Since this is a major positive development announcement, and it is not a formal SEC filing like 10-K or a specific report like AR, I will classify it as an Earnings Release (ER) as it serves the function of announcing a major positive operational/regulatory milestone that impacts future revenue potential, which is common practice for press releases of this nature. The document length (7683 chars) is substantial enough that it is not just a brief notification (RPA).
2024-07-26 French
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
Capital/Financing Update Classification · 95% confidence The document is titled "GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial" (GENFIT: Semi-annual statement of the liquidity contract entered into with Crédit Industriel et Commercial). It explicitly reports on the status and transactions (purchases and sales of shares and amounts in EUR) related to a liquidity contract for the first semester of 2024, ending June 30, 2024. This type of regular disclosure regarding market making or liquidity provision activities, especially when presented as a periodic statement (semi-annual), is a specific type of corporate action disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR). It details specific financial/market operations related to share management, which aligns best with Capital/Financing Update (CAP) or potentially a specialized regulatory filing. Given the focus on the liquidity contract management and the periodic nature of the report (semi-annual statement), it fits best under Capital/Financing Update (CAP) as it relates directly to capital management tools, or potentially Regulatory Filings (RNS) if no better fit exists. However, since it details the execution of a financing/capital management agreement (liquidity contract), CAP is the most appropriate specific category over the general RNS fallback. The document is comprehensive (19,198 chars) and contains the full details, not just an announcement of a report.
2024-07-09 French
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Transaction in Own Shares Classification · 98% confidence The document is titled "GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial" and provides detailed figures regarding share transactions (buy side and sell side) executed under a liquidity contract for the first half of 2024, ending June 30, 2024. This type of disclosure relates to the management of the company's own shares (share buybacks/sales) under a specific agreement, often required by market regulations. The detailed appendix shows daily transaction data for the first half of the year. This aligns precisely with the definition of 'Transaction in Own Shares' (POS), which covers share repurchase or issuance activities. It is not an Earnings Release (ER) or Interim Report (IR) as it focuses solely on liquidity management transactions, not operational or comprehensive financial results. It is also not a Director's Dealing (DIRS) as it concerns the company's own shares under a contract, not individual director trades. Therefore, POS is the most appropriate classification.
2024-07-09 English
GENFIT : Les nouvelles recommandations de pratique clinique de l'EASL-EASD-EASO pour la MASLD incluent NIS2+® comme outil-clé pour la détection de la MASH à risque
Regulatory Filings Classification · 95% confidence The document is a press release from GENFIT dated June 17, 2024, announcing that the NIS2+® diagnostic tool has been included in new European clinical practice recommendations for MASLD/MASH. It discusses scientific validation, regulatory context (FDA approval of resmetirom), and provides background on MASH, NIS2+®, and GENFIT. This type of announcement, which communicates significant business/scientific updates, regulatory milestones, or clinical trial results outside of mandated periodic financial reports (like 10-K or IR), typically falls under a general press release category. Since it is not a formal financial report (10-K, IR, MRQ), a specific regulatory filing (RNS), or a presentation (IP), and it is not announcing a dividend (DIV) or management change (MANG), the most appropriate classification is a general Regulatory Filing (RNS) as a catch-all for significant corporate news releases, or potentially an Investor Presentation (IP) if it were structured as a slide deck, but here it reads like a news announcement. Given the content is a major scientific/business update disseminated via press release, RNS (Regulatory Filings/Announcements) is the best fit among the provided options for non-standard, material corporate news.
2024-06-17 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.